A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Metastatic Breast CancerMetastatic Ovarian CancerMetastatic Pancreatic CancerAdvanced Solid TumorMetastatic Liver CancerMetastatic Endometrial Cancer
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- EtiraRx Australia Pty Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT06533332
- Locations
- 🇦🇺
The Kinghorn Cancer Center, Sydney, New South Wales, Australia
🇦🇺MQ Health Medical Oncology and Clinical Trials/Macquarie University, Sydney, New South Wales, Australia
🇦🇺Cancer Research SA, Adelaide, South Australia, Australia
© Copyright 2025. All Rights Reserved by MedPath